Thetford Mines, Quebec – March 10, 2021 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce, as previously disclosed in its press release dated November 18, 2020, that its wholly owned subsidiary, Groupe Technologique KDA Inc. (“Tech KDA”) has entered into an asset purchase and rights assignment agreement (the “Asset Purchase Agreement”) with ZoomMed Médical Inc. (“ZoomMed Médical”) under which Tech KDA agreed to acquire, subject to certain conditions, the ZRx Prescriber and ownership rights, to develop, commercialize and exploit the ZRx Prescriber in the United States, Europe and United Kingdom, in consideration for 20,000,000 Class A shares (the “KDA Shares”) of KDA’s share capital (the “Transaction”).